{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:28:38Z","timestamp":1789954118801,"version":"4.0.1"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,8]]},"abstract":"ABSTRACT<\/jats:title>\n \n Multidrug-resistant\n Klebsiella pneumoniae<\/jats:named-content>\n carbapenemase (KPC)-producing\n Enterobacteriaceae<\/jats:named-content>\n are endemic to hospitals in New York City and other regions. RPX7009 is a novel \u03b2-lactamase inhibitor with activity against serine carbapenemases. We tested the activity of meropenem plus RPX7009 against 4,500 recent Gram-negative clinical isolates from 11 New York City hospitals. The meropenem-RPX7009 combination was found to have excellent\n in vitro<\/jats:italic>\n activity against\n Escherichia coli<\/jats:named-content>\n ,\n K. pneumoniae<\/jats:named-content>\n , and\n Enterobacter<\/jats:named-content>\n spp., including multidrug-resistant (MDR) KPC-producing strains. Overall, 131\/133 (98.5%) KPC-producing\n Enterobacteriaceae<\/jats:named-content>\n strains were inhibited by meropenem (\u22641 \u03bcg\/ml) plus RPX7009 (8 \u03bcg\/ml). In a limited number of strains, the combination appeared to have reduced activity against KPC-producing\n K. pneumoniae<\/jats:named-content>\n isolates with diminished\n ompK35<\/jats:italic>\n and\n ompK36<\/jats:italic>\n expression. The addition of RPX7009 did not affect the activity of meropenem against\n Acinetobacter baumannii<\/jats:named-content>\n and\n Pseudomonas aeruginosa<\/jats:named-content>\n . The meropenem-RPX7009 combination shows promise as a novel agent against KPC-producing\n Enterobacteriaceae<\/jats:named-content>\n and deserves further study. Other approaches will be needed to address multidrug-resistant\n A. baumannii<\/jats:named-content>\n and\n P. aeruginosa<\/jats:named-content>\n , which typically possess different mechanisms of carbapenem resistance.\n <\/jats:p>","DOI":"10.1128\/aac.00843-15","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T13:55:09Z","timestamp":1433253309000},"page":"4856-4860","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":140,"title":["Activity of Meropenem Combined with RPX7009, a Novel \u03b2-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City"],"prefix":"10.1128","volume":"59","author":[{"given":"Amabel","family":"Lapuebla","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawole","family":"Olafisoye","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cortes","sequence":"additional","affiliation":[{"name":"The Dr. James J. Rahal, Jr., Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Urban","sequence":"additional","affiliation":[{"name":"The Dr. James J. Rahal, Jr., Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quale","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Landman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku048"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110655"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01464-06"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis543"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1633-1641.2006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01684-07"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014556652"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt118"},{"key":"e_1_3_2_11_2","volume-title":"CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_12_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/421495"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2002.00401.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.15-22.2004"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.012575-0"},{"key":"e_1_3_2_18_2","volume-title":"Effect of the \u03b2-lactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae, abstr C-777","author":"Castanheira M","year":"2014","unstructured":"Castanheira M, Becker HK, Rhomberg PR, Jones RN. 2014. Effect of the \u03b2-lactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae, abstr C-777. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014."},{"key":"e_1_3_2_19_2","first-page":"S110","volume-title":"Open Forum Infect Dis","volume":"1","author":"Castanheira M","year":"2014","unstructured":"Castanheira M, Rhomberg PR, Watters A, Jones RN. 2014. In vitro activity of meropenem\/RPX7009, a carbapenem\/\u03b2-lactamase inhibitor combination tested against contemporary populations of Enterobacteriaceae and KPC-producing strains. Open Forum Infect Dis 1(Suppl 1):S110."},{"key":"e_1_3_2_20_2","volume-title":"Intersci Conf Antimicrob Agents Chemother","author":"Tarazi Z","year":"2014","unstructured":"Tarazi Z, Sabet M, Rubio-Aparicio D, Nolan T, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. 2014. Efficacy of simulated human exposures of Carbavance (meropenem-RPX7009) against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model, abstr F-959. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014."},{"key":"e_1_3_2_21_2","volume-title":"Intersci Conf Antimicrob Agents Chemother","author":"Sabet M","year":"2014","unstructured":"Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. 2014. In vivo efficacy of carbavance (meropenem\/RPX7009) against KPC-producing Enterobacteriaceae, abstr F-958. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp029"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks079"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00843-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00843-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:02:47Z","timestamp":1645484567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00843-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1128\/AAC.00843-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.00843-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"2015-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}